Fentanyl sublingual - Sosei

Drug Profile

Fentanyl sublingual - Sosei

Alternative Names: AD-923; SGX-2001; SRSS-001

Latest Information Update: 08 Oct 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sosei R&D
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Cancer pain

Most Recent Events

  • 08 Aug 2013 Biomarkers information updated
  • 08 Oct 2009 Fentanyl sublingual (AD 923), as well as device for its administration, are licensed to Pharmasol
  • 26 Dec 2008 Sosei reacquires commercialisation rights for fentanyl sublingual (AD 923) from Mundipharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top